About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New 'checkpoint' Model to Develop Drugs for Genetic Disorders

by Anjali Aryamvally on December 19, 2017 at 1:33 PM
Font : A-A+

New 'checkpoint' Model to Develop Drugs for Genetic Disorders

A new 'checkpoint' model can be used to identify potential treatments for genetic disorders such as cystic fibrosis and Duchenne muscular dystrophy (DMD) has been proposed by a team of Bradford scientists.

These disorders can be caused by a particular type of mutation in DNA, called a 'nonsense mutation'. This results in a pre-mature 'stop' instruction being issued to the cellular machinery that translates DNA into proteins - the molecules that do most of the work in the body's cells. This means the protein is unable to function normally, or may not even be produced at all, resulting in conditions which can be devastating for patients and their families.

Advertisement


Many of the new drugs under development to treat these genetic disorders aim to boost production of these proteins. They work by making the cellular machinery less sensitive to the premature 'stop' instructions, with the aim of reducing or eliminating the patient's symptoms. The research team at the University of Bradford has come up with a new model that can be used to develop screening tests for both genes and chemical compounds, published in the journal Human Molecular Genetics. They believe this could help scientists more effectively spot promising targets for drug development work. In their model, a compound needs to by-pass the pre-mature stop instruction only once in order to be useful in the treatment of genetic disorders. Importantly, the compounds would not bypass all stop signals, as this could allow harmful proteins to be generated.

Dr Talat Nasim, leading the research, explains: "Our model acts like a simple roadside checkpoint. Compounds which can fulfil certain criteria will enable some proteins to get past the pre-mature stop signal. Even a small amount of the right proteins would be enough to give some therapeutic protection, and that would lessen the symptoms of the disorder. Our model does not support the translational machinery to be re-programmed in such a way that it by-passes all stop signals. This would potentially generate proteins with many more mutated amino acids.
Advertisement

The team has also developed a number of more accurate cell-based screening assays based on this model. Using these techniques, they have screened hundreds of genes and have already identified two that are involved in the translation process and that could be targeted for drug development. The researchers have also screened more than 1000 existing FDA approved drugs collected by the National Institute of Neurological Disease Syndrome (NINDS) to see if they could be repurposed to treat genetic disorders caused by nonsense mutations - though none were shown to have any potential in this regard .

Additionally, the team has tested a compound called PTC124, first discovered in 2007, and reported in the journal Nature. The compound has been shown to boost production of the dystrophin protein in young patients with Duchenne muscular dystrophy caused by nonsense mutations. It is thought that PTC124 does this by making the cell by-pass the premature stop signal. Using the new methods, however, the researchers found that the compound does not work in this way. According to Dr Nasim the compound, developed under the brand name Translarna, may benefit patients via other mechanisms. The drug has conditional approval from the European Medicine's Agency. It is currently available in the UK and has been recommended as a treatment for young DMD patients with nonsense mutations by the National Institute for Health and Care Excellence (NICE). In the US, however the Food and Drug Administration has refused to grant a licence for the drug.

Dr Nasim believes the model developed by his team could help reduce the high costs of drug development work in this area by ruling out compounds that are unlikely to have any therapeutic benefit at an earlier stage in the process.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
International Day of Persons with Disabilities 2021 - Fighting for Rights in the Post-COVID Era
Effect of Blood Group Type on COVID-19 Risk and Severity
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Genetics and Stem Cells Drugs Banned in India Weaver Syndrome Porphyria Christianson Syndrome Williams Syndrome Basics of Rare Diseases Ectodermal Dysplasia Genetics of Alzheimer´s disease 

Recommended Reading
Basics of Rare Diseases
Rare or orphan diseases are least understood of all chronic diseases. They are more common than ......
Genetic Counseling
Encyclopedia section of medindia gives general info about Genetic counseling ...
India Introduces New Low-Cost Genetic Screening Test To Reduce Genetic Disorders
A low-cost screening test is introduced for couples that helps in reducing the burden of genetic ......
Gene Therapy Can Increase Life Span of Genetic Disorders
Adrenoleukodystrophy, an X-linked genetic disease that usually affects boys can be treated with ......
Christianson Syndrome
Christianson syndrome is a condition that occurs due to mutations (abnormal changes) in the gene SLC...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Ectodermal Dysplasia
Ectodermal dysplasias are a group of genetic disorders that involve defects in sweat glands, hair, t...
Genetics of Alzheimer´s disease
There are numerous genes that have been discovered that are associated with Alzheimer’s disease and ...
Porphyria
Porphyria or vampire disease or is a group of inherited diseases that cause symptoms of the nervous ...
Weaver Syndrome
Weaver syndrome is a genetic disorder in which children show accelerated bone growth, advanced bone ...
Williams Syndrome
Williams syndrome is a rare genetic disorder due to a deletion in the long arm of chromosome 7....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use